Endo “continues to be encouraged” that downward pricing pressures the company has experienced in the US generic retail market “over the past few years appear to be stabilising”, president and chief executive officer Paul Campanelli has said.
“We’ve seen promising early signals and remain cautiously optimistic,” he told investors as Endo presented second quarter results, echoing previous...






